CN1533268A - 含有邻苯二甲酸羟丙基甲基纤维素聚合物的固体分散体的药物组合物 - Google Patents

含有邻苯二甲酸羟丙基甲基纤维素聚合物的固体分散体的药物组合物 Download PDF

Info

Publication number
CN1533268A
CN1533268A CNA028056256A CN02805625A CN1533268A CN 1533268 A CN1533268 A CN 1533268A CN A028056256 A CNA028056256 A CN A028056256A CN 02805625 A CN02805625 A CN 02805625A CN 1533268 A CN1533268 A CN 1533268A
Authority
CN
China
Prior art keywords
polymer
chemical compound
compound
salt
solid dispersion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028056256A
Other languages
English (en)
Chinese (zh)
Inventor
N
N·巴特曼
J·卡希尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1533268A publication Critical patent/CN1533268A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA028056256A 2001-02-27 2002-02-25 含有邻苯二甲酸羟丙基甲基纤维素聚合物的固体分散体的药物组合物 Pending CN1533268A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0104752.1 2001-02-27
GBGB0104752.1A GB0104752D0 (en) 2001-02-27 2001-02-27 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
CN1533268A true CN1533268A (zh) 2004-09-29

Family

ID=9909545

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028056256A Pending CN1533268A (zh) 2001-02-27 2002-02-25 含有邻苯二甲酸羟丙基甲基纤维素聚合物的固体分散体的药物组合物

Country Status (14)

Country Link
US (1) US20040138231A1 (xx)
EP (1) EP1365746A1 (xx)
JP (1) JP2004527489A (xx)
KR (1) KR20040011469A (xx)
CN (1) CN1533268A (xx)
BR (1) BR0206960A (xx)
CA (1) CA2435815A1 (xx)
GB (1) GB0104752D0 (xx)
IL (1) IL156830A0 (xx)
MX (1) MXPA03006746A (xx)
NO (1) NO20033782D0 (xx)
NZ (1) NZ527080A (xx)
WO (1) WO2002067904A1 (xx)
ZA (1) ZA200305386B (xx)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104188893A (zh) * 2014-08-18 2014-12-10 赵明亮 一种盐酸环丙沙星口服固体制剂及其制备工艺

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
WO2004105728A2 (en) * 2003-05-27 2004-12-09 Ranbaxy Laboratories Limited Solid dispersions of cefpodoxime proxetil and processes for their preparation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20110034478A1 (en) * 2008-04-15 2011-02-10 Schering-Plough Corporation Oral Pharmaceutical Compositions in a Solid Dispersion Comprising Preferably Posaconazole and HPMCAs
UA106878C2 (uk) * 2008-10-07 2014-10-27 Астразенека Юк Лімітед Фармацевтична композиція, що містить 4-[3-(4-циклопропанкарбонілпіперазин-1-карбоніл)-4-фторбензил]-2н-фталазин-1-он або його сіль, або сольват, у твердій дисперсії з матричним полімером коповідоном
US20170087134A1 (en) * 2010-07-12 2017-03-30 Salix Pharmaceuticals, Ltd Formulations of rifaximin and uses thereof
CN110072525B (zh) 2016-09-30 2022-12-02 萨利克斯药品公司 利福昔明的固态分散形式

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57120518A (en) * 1981-01-19 1982-07-27 Tanabe Seiyaku Co Ltd Preparation of microcapsule
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
TW212139B (xx) * 1991-04-15 1993-09-01 Yamanouchi Pharma Co Ltd
KR0182801B1 (ko) * 1991-04-16 1999-05-01 아만 히데아키 고체 분산체의 제조방법
US6312726B1 (en) * 1993-08-20 2001-11-06 Nippon Shinyaku Co., Ltd. Gastric remaining preparation, swollen molding, and production process
DE69921994T2 (de) * 1998-05-02 2005-12-01 Astrazeneca Ab Heterozyklische verbindungen mit faktor xa hemmender wirkung
PT1239831E (pt) * 1999-12-23 2013-01-23 Mayne Pharma International Pty Ltd Composições farmacêuticas melhoradas para fármacos fracamente solúveis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104188893A (zh) * 2014-08-18 2014-12-10 赵明亮 一种盐酸环丙沙星口服固体制剂及其制备工艺

Also Published As

Publication number Publication date
NO20033782L (no) 2003-08-26
NO20033782D0 (no) 2003-08-26
IL156830A0 (en) 2004-02-08
JP2004527489A (ja) 2004-09-09
BR0206960A (pt) 2004-03-09
MXPA03006746A (es) 2003-10-24
WO2002067904A1 (en) 2002-09-06
NZ527080A (en) 2005-02-25
US20040138231A1 (en) 2004-07-15
GB0104752D0 (en) 2001-04-18
EP1365746A1 (en) 2003-12-03
KR20040011469A (ko) 2004-02-05
ZA200305386B (en) 2004-10-11
CA2435815A1 (en) 2002-09-06

Similar Documents

Publication Publication Date Title
ES2340053T3 (es) Formas de asministracion farmaceuticas solidas asministrables por via oral que contienen rivaroxaban con liberacion modificada.
US20200330600A1 (en) Pharmaceutical composition
EP2493456B1 (en) Solid dispersion of rifaximin
US20170027931A1 (en) Posaconazole pharmaceutical compositions and preparation methods, uses and pharmaceutical formulations thereof
KR101797776B1 (ko) 고형 제제
US20230255964A1 (en) Extended release dosage forms for tyk2 inhibitors
RU2006136020A (ru) Фармацевтические композиции
KR20220027268A (ko) 난수용성 화합물용 약제학적 조성물
KR20120029428A (ko) 아픽사반의 투여 형태
KR20150097792A (ko) 개선된 생체이용률을 갖는 약학 조성물
WO2015152433A1 (en) Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
US9744170B2 (en) Solid antiviral dosage forms
CN1474702A (zh) 含有嵌段共聚物的口服药物组合物
CN1533268A (zh) 含有邻苯二甲酸羟丙基甲基纤维素聚合物的固体分散体的药物组合物
US20080138404A1 (en) Extended release formulations of carvedilol
JP2020529464A (ja) ３−フルオロ−４−［７−メトキシ−３−メチル−８−（１−メチル−１Ｈ−ピラゾール−４−イル）−２−オキソ−２，３−ジヒドロ−イミダゾ［４，５−ｃ］キノリン−１−イル］−ベンゾニトリル含む医薬製剤
ES2663721T3 (es) Formulaciones de olmesartán
EP3796904B1 (en) Sustained release acemetacin compositions
US20160287558A1 (en) Oral pharmaceutical form for preventing vascular diseases, tablet as pharmaceutical form and gelatin capsule as pharmaceutical form
CN101254169A (zh) 含抗结核病药物的缓释剂
KR20190064208A (ko) 피마살탄을 포함하는 고체 분산체
US20220241208A1 (en) Pharmaceutical compositions for the treatment of hbv
AU2002233882A1 (en) Pharmaceutical composition which comprise a solid dispersion of a hydroxypropylmethylcellulose phthalate polymer
CN1857218A (zh) 含抗结核病药物的缓释剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication